Suchen
RAPT Therapeutics Inc
RAPTZur Watchlist hinzufügen
58.020USD
0.0000.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.68BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über RAPT Therapeutics Inc Unternehmen
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
RAPT Therapeutics Inc Informationen
BörsenkürzelRAPT
Name des UnternehmensRAPT Therapeutics Inc
IPO-datumOct 31, 2019
CEOWong (Brian)
Anzahl der mitarbeiter68
WertpapierartOrdinary Share
GeschäftsjahresendeOct 31
Addresse561 Eccles Ave
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16504899000
Websitehttps://rapt.com/
BörsenkürzelRAPT
IPO-datumOct 31, 2019
CEOWong (Brian)
Führungskräfte von RAPT Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
-100.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von RAPT Therapeutics Inc?
Die fünf größten Anteilseigner von RAPT Therapeutics Inc sind: Dr. William (Bill) Ho, M.D., Ph.D.
Wie viele Institutionen halten Anteile an RAPT Therapeutics Inc (RAPT)?
Mit Stand vom 2026Q1 halten 301 Institutionen Anteile an RAPT Therapeutics Inc, mit einem Gesamtmarktwert von etwa 29.16M, was 100.68% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 8207720.00 gestiegen.